Drug Profile
Research programme: PARP inhibitors - Kyorin Pharmaceutical
Alternative Names: KCL-440Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Kyorin Pharmaceutical
- Class
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cerebral infarction
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cerebral-infarction in Japan (IV)
- 01 Mar 2006 A preclinical study has been added to the pharmacokinetics and Neurological disorders pharmacodynamics sections
- 22 Dec 2005 Preclinical trials in Cerebral infarction in Japan (IV)